Exagen Inc. to Participate in Upcoming Investor Conference
Exagen (Nasdaq:XGN) announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on August 11, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Exagen (Nasdaq:XGN) announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on August 11, 2026. The company will host a Fireside Chat at 8:30 a.m. ET, with live and archived webcasts available on its investor relations website.
Details
News Market Reaction – XGN
On Jul 28, the day this news came out, XGN closed 1.14% above the previous close. Argus tracked a trough of -2.4% from its starting point during tracking. Our momentum scanner recorded 7 alerts for this stock that day.
Data tracked by StockTitan Argus for the Jul 28 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conference:
Canaccord Genuity 46th Annual Growth Conference – Boston, MA
Date: August 11, 2026
Fireside Chat at 8:30am ET
A live and archived webcast of the Fireside Chat will be available on Exagen’s Investor Relations website at investors.exagen.com.
About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease earlier and with greater accuracy. Exagen’s CLIA-certified, CAP-accredited laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
For more information, visit Exagen.com or follow Exagen on LinkedIn.
Investors:
Tina Jacobsen, CFA
IR@exagen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.